Article

State of Science Summit- Bladder/Prostate: Chaired by Alicia Morgans, MD, MPH

In Partnership With:

State of Science Summit- Bladder/Prostate: Chaired by Alicia Morgans, MD, MPH

State of Science Summit- Bladder/Prostate: Chaired by Alicia Morgans, MD, MPH

Speakers

  • Stephanie Berg, DO | Dana-Farber Cancer Institute
  • Bradley McGregor, MD | Dana-Farber Cancer Institute
  • Atish Choudhury, MD, PhD | Dana-Farber Cancer Institute
  • Praful Ravi, MB, BChir, MRCP | Dana-Farber Cancer Institute

Topics

  • Immunotherapy in the Management of mUC
  • Treating mUC with ADCS
  • mCRPC: Shift in Treatment Paradigm with PARP inhibitors
  • Recent Advances in mHSPC
  • PSMA Targeted Therapies

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science Summits. Click here to listen to our latest episodes!

Related Videos
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Sara M. Tolaney, MD, MPH
Brian I. Rini, MD, FASCO
Marc Machaalani, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Razane El Hajj Chehade, MD
Antonio Cigliola, MD
Brian I. Rini, MD, FASCO
Related Content
Sara M. Tolaney, MD, MPH
July 26th 2024

From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Lajos Pusztai, MD, DPhil
July 25th 2024

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School
March 28th 2024

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

Adrienne G. Waks, MD
July 24th 2024

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

Adrienne G. Waks, MD, of Dana-Farber Cancer Institute
July 23rd 2024

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?